Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Frequently Asked Questions / Types of Cancer / Pediatric Cancers / Leukemias: Acute Lymphocytic Leukemia (ALL)
Last Modified: July 25, 2004
![]()
Dear OncoLink "Ask The Experts,"
My son (6 yrs old) has been diagnosed with ALL (Acute Lymphblastic Leukaemia) just 2 months back (6th May 2004). The doctors here are following the CCCG 1991 protocol. At the end of the induction phase, he was paralyzed from hip below. The doctors stopped chemotherapy till such he improved. He is able to walk on his own now, but still has some weakness in his knees. His pediatric oncologist thinks the temporary paralysis was either due to a) Vincristine (VCR) toxicity, b) Intrathecal (IT) methotrexate (MTX) toxicity.
They have restarted the chemotherapy with half dose of VCR (IV push). They also said that they will stop the IT MTX for a while, but put him on IT ARA C (Cytarabine) and then slowly reintroduce IT MTX. If he still does not tolerate, then the doctors have recommended prophylactic cranial RT. But the Radiologists at his treating hospital are not in favor to give him cranial radiation since my son has had the above mentioned toxicity to VCR or IT MTX. As a concerned parent, I do not know where my son stands in the treatment phase.
Anna Meadows, MD, Pediatric Oncologist at the Children's Hospital of Philadelphia and Director of the Abramson Cancer Center of the University of Pennsylvania's Survivorship Research Program, responds:
Your son is getting treatment with the best protocol we now know. However, there are some children who have exaggerated responses to some of the drugs. We have seen children with your son's toxicity, and mostly it was due to VCR, not MTX. Although it is difficult to give advice from a distance, when children experience this toxicity at the Children's Hospital of Philadelphia (CHOP) we would recommend continuing with Ara C for now until the child is no longer getting so much VCR. We would typically then introduce MTX IT when in the maintenance phase of treatment. We would not recommend cranial radiation at this time, as many children still have a very good chance of not relapsing. We would reserve radiation for later if needed when children are older and tolerate it better. These are general guidelines we follow at CHOP, but specific recommendations can only be made by your treating physician.
Ms. Hollis discusses the role of the nurse practitioner in oncology care. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

